Before The Bell: (SHPH) Flexes Its Muscles On Approx. 35% Move—Surpassing Key Technical Levels

*Sponsored Just Announced: Krypton Street Initiates Coverage on (SHPH)! Here’s Why… A Recent Approx. 57% Move From $0.3501 To $0.55 In Just Six Sessions  Shows How Quickly (SHPH) Can React. Fewer Than 3.5M Shares In Circulation Puts (SHPH) In Ultra-Low Float Territory. Projected Growth To $5.68B In The Glioblastoma Space Aligns With (SHPH)’s Current Direction. Recent Progress In A Phase 2 Trial Positions (SHPH) In A High-Need  Area Of Oncology. April 11, 2025 Dear Reader, Please tell me you pulled up (SHPH) and have it on your screen. There’s about 15 minutes to go before the bell rings.  (SHPH) surpassed several key moving averages on its approximately 35% overnight move from $.40 to $.54 this morning’s early session, including its 5-Day, 20-Day, and 50-Day. Shortly after yesterday’s closing bell, Shuttle Pharmaceuticals (Nasdaq: SHPH) announced a key intellectual property filing that could advance its position in PSMA-targeted oncology. The company’s new patent, titled “PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy,” aims to sharpen both diagnosis and treatment of metastatic prostate cancer through enhanced targeting of PSMA antigens.  The project was developed in collaboration with Dr. Alan Kozikowski, one of the minds behind Pylarify and Pluvicto. As part of its broader strategy, (SHPH) is also progressing its PC-RAD blood test and PSMA-B dual-use molecule, with academic support from UCSF. The company appears to be carving out a lane in a market forecast to reach $2B in PSMA-related therapies alone. Keep reading to get up to speed on why we’re highlighting (SHPH) right now.  While most eyes turn way after the bell—we have all eyes on (SHPH) right now. Just outside Washington, in a biotech corridor that’s quietly become one of the most concentrated in the country, a lesser-known name has started to show unmistakable signs of traction. Gaithersburg, Maryland might not make headlines often, but inside this tight radius—where over 200 biotech firms cluster near the NIH and FDA—there’s a story beginning to take shape. It involves a thin float, a recent move that raised eyebrows, and a company operating in one of the most serious areas of medical need. You likely haven’t heard the name yet.  But that’s part of the reason we’re watching it so closely. As of today, we’re initiating coverage on Shuttle Pharmaceuticals (Nasdaq: SHPH). And based on what we’re seeing, this may be one of the most under-the-radar names in the space right now. With Less Than 3.5M Shares In The Float, Every Move Matters… One of the first things that stands out? Supply—or rather, the lack of it. As of now, there are fewer than 3.5M shares in (SHPH)’s public float.  That puts it in ultra-low float territory, a space where even modest interest can trigger significant movement simply due to scarcity. And recently?  That scenario has already started to play out.  An approximate 57% move inside of just 6 sessions, from $.3501 on 3/31/2025 to $.55 on 4/7/2025, makes a case for bullish momentum potential. Early-Stage Progress in a Sector That’s Heating Up Fast… With a market cap under $2.5M, (SHPH) currently sits in the category of companies that often slip under the radar—until a key moment changes that. For (SHPH), several of those moments are now stacking up. The company recently announced a milestone in patient enrollment for its Phase 2 trial of Ropidoxuridine, a radiation sensitizer being tested for use in patients with glioblastoma, an aggressive and highly challenging form of brain cancer. This development aligns with the broader industry trend: the global glioblastoma multiforme (GBM) treatment market is projected to grow from $2.48B in 2024 to $2.74B in 2025, reflecting a compound annual growth rate (CAGR) of 10.2%. ​ As of the last update, 40% of the targeted patients in the randomized portion of the study have been enrolled.  Clinical sites include major research centers like Georgetown University Medical Center and University of Virginia Cancer Center. This development is especially timely. The global glioblastoma treatment space is entering a new phase, as limitations of traditional options like surgery, radiation, and chemotherapy continue to spark growing interest in more targeted and innovative approaches. Recurrent cases are on the rise, and each year, more than 200,000 new glioma diagnoses are reported globally—a trend that underscores the need for more effective solutions. Looking ahead, the global glioblastoma multiforme (GBM) treatment market is projected to exceed $3B in 2025—and may approach $5.68B by 2033, reflecting growth of nearly 89% driven by advancements in personalized medicine, immunotherapy, and novel treatment platforms. It’s Not Just One Program—The Pipeline Here Runs Deep… (SHPH)’s pipeline doesn’t stop at one product. They’re also advancing SP-2-225, a selective HDAC6 inhibitor being developed to enhance immune system responses in combination with radiation therapy.   Early-stage research suggests this approach may be able to trigger systemic immune activity—not just local control. Meanwhile, they’re developing diagnostic tools like: PC-RAD, a blood-based test for assessing radiation therapy outcomes in prostate cancer PSMA-B, a dual-use molecule that could be used for both imaging and treatment of metastatic disease A recent collaboration with UCSF (University of California, San Francisco) is helping accelerate development of PSMA-B. Strategic Moves at the Top… In March 2025, (SHPH) announced the appointment of Christopher Cooper as interim Co-CEO.  His role?   Support the next phase of the company’s expansion and corporate visibility.  Cooper brings over 27 years of experience working with public and private firms. Shortly after, the company completed a $5.75M underwritten offering, bringing in additional funding to support its pipeline and future activities. When Location Powers Progress—This One’s in the Right Zip Code… (SHPH) didn’t end up in Maryland by accident.  This region: Has one of the highest concentrations of STEM professionals in the U.S. Anchors a $17B life sciences industry with an innovation-first culture Offers close access to NIH and FDA, enabling smoother regulatory and clinical collaboration This isn’t just about one company—it’s about being in the right place, with the right people, working on real-world solutions. Bottom Line… There’s a reason this company landed on our radar. Between its lean float, recent clinical progress, added leadership depth, and new capital, (SHPH) may be entering a phase where under-the-surface developments begin catching wider attention. We have officially announced coverage on (SHPH) and have it at the top of our watchlist right now—you may want to do the same. 5 Reasons Why (SHPH) Is Topping Our Watchlist Right Now… 1. Ultra-Low Float With Confirmed Movement: With fewer than 3.5M shares in circulation, (SHPH) sits in ultra-thin float territory—and it’s already shown what that can mean, climbing from $0.3501 to $0.55 in just six sessions. 2. Real Progress in a Growing Global Market: (SHPH)’s Phase 2 trial targeting glioblastoma—a condition with rising global incidence—aligns with a treatment market projected to grow from over $3B in 2025 to nearly $5.68B by 2033. 3. Pipeline Depth and Academic Collaboration: In addition to its lead program, (SHPH) is developing a selective HDAC6 inhibitor and diagnostic tools like PC-RAD and PSMA-B, with support from institutions like UCSF. 4. Experienced Leadership With Fresh Capital: A new interim Co-CEO with 27+ years of experience joined in March 2025, followed by a $5.75M underwritten raise aimed at accelerating near-term developments. 5. Strategically Positioned in a Biotech Epicenter: Headquartered in Gaithersburg, Maryland—home to 200+ biotech firms and minutes from the NIH and FDA—(SHPH) benefits from access to talent, infrastructure, and regulatory resources. Take A Quick Look At (SHPH)... With multiple catalysts now in play—from clinical progress and pipeline depth to recent leadership changes and a capital infusion— Shuttle Pharmaceuticals (Nasdaq: SHPH) has positioned itself as a name worth watching closely. Its ultra-low float, recent chart action, and presence in a high-growth medical segment backed by a multibillion-dollar global forecast only add to the case for closer inspection. We have (SHPH) at the top of our screens right now.  Take a quick look at (SHPH).  (SHPH) surpassed several key moving averages on its approximately 35% overnight move from $.40 to $.54 this morning’s early session, including its 5-Day, 20-Day, and 50-Day.  And please keep an eye out for my next update—it could be on its way to you at any moment this morning. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 04/10/2025 and ending on 04/11/2025 to publicly disseminate information about (SHPH:US) via digital communications. Under this agreement, Media 1717 LLC has been paid ten thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC and their member own shares of (SHPH:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/shph/#details

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice